Literature DB >> 15837974

Role of positron emission tomography in lymphoma.

Malik E Juweid, Bruce D Cheson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15837974     DOI： 10.1200/JCO.2005.01.904

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  27 in total

Review 1.  Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma.

Authors:  Andrea Gallamini
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

Review 2.  PET in lymphoma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

3.  Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT.

Authors:  Jing Gu; Pek-Lan Khong; Silun Wang; Queenie Chan; Wailun Law; Jingbo Zhang
Journal:  Mol Imaging Biol       Date:  2010-09-25       Impact factor: 3.488

4.  [F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model.

Authors:  Coralie Chaise; Emmanuel Itti; Yolande Petegnief; Evelyne Wirquin; Christiane Copie-Bergman; Jean-Pierre Farcet; Marie-Hélène Delfau-Larue; Michel Meignan; Jean-Noël Talbot; Valérie Molinier-Frenkel
Journal:  Cancer Immunol Immunother       Date:  2006-12-14       Impact factor: 6.968

Review 5.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

6.  Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Authors:  Bing Bai; Hui-Qiang Huang; Qi-Chun Cai; Wei Fan; Xiao-Xiao Wang; Xu Zhang; Ze-Xiao Lin; Yan Gao; Yun-Fei Xia; Ying Guo; Qing-Qing Cai; Wen-Qi Jiang; Tong-Yu Lin
Journal:  Med Oncol       Date:  2013-01-18       Impact factor: 3.064

7.  Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.

Authors:  Klaus Strobel; Reinhard Dummer; Hans C Steinert; Katrin Baumann Conzett; Karin Schad; Marisol Pérez Lago; Jan D Soyka; P Veit-Haibach; Burkhardt Seifert; V Kalff
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-06       Impact factor: 9.236

8.  The utility of body FDG PET in staging primary central nervous system lymphoma.

Authors:  Nimish A Mohile; Lisa M Deangelis; Lauren E Abrey
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

9.  Cellular density evaluation for malignant lymphoma using equivalent cross-relaxation rate imaging - initial experience.

Authors:  Hideyuki Nishiofuku; Shigeru Matsushima; Yoshitaka Inaba; Hidekazu Yamaura; Yozo Sato; Yasuo Morishima; Kimihiko Kichikawa
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

Review 10.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.